- Genprex Inc Global One Media Interview TranscriptJun 22, 2023
- Genprex Inc at Sidoti & Company May Micro-Cap Virtual Conference TranscriptMay 11, 2023
- Genprex Inc KOL Event: Novel Gene Therapy to Treat Type 1 Diabetes TranscriptApr 12, 2023
- Genprex Inc at LD Micro Main Event TranscriptOct 26, 2022
- Genprex Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Genprex Inc at LD Micro Invitational Conference (Virtual) TranscriptJun 08, 2022
- Genprex Inc at Noble Capital Markets Investor Conference (Virtual) TranscriptApr 20, 2022
- Genprex Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 29, 2021
- Genprex Inc C-Suite Interview with Noble Capital Markets TranscriptApr 22, 2021
- Cell and Gene Meeting on Mesa - Genprex TranscriptJan 08, 2021
- Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies TranscriptNov 06, 2020
- Genprex (GNPX) Virtual Road Show with CEO Rodney Varner TranscriptSep 15, 2020
- Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir TranscriptAug 04, 2020
Genprex Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Thanks. Good morning. My name is Ryan Confer; I'm the Chief Financial Officer of Genprex. And today, I'd like to share with you how we are pioneering gene therapies for large patient populations in cancer and in diabetes.
This is our forward-looking statement slide. I'm not going to spend too much time on this, but for any of you that are interested more in Genprex or considering an investment opportunity, I'd encourage you to go to our corporate website, genprex.com, read through this. Our slide deck is also on our corporate website, as well as our recent SEC filings that would include all of our risk factors.
This is a financial summary slide for us. We are a NASDAQ capital markets traded company under the ticker GNPX. I think the most crucial point on this slide is our cash balance of $38.6 million at the end of 2021, which is a pretty healthy balance going into the 2022 year.
So I think this is probably the most compelling slide in the whole deck. It really showcases our key differentials in terms of why we believe we have such significant
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)